According to JNJ, the increase in sales was “driven primarily by the market recovery from Covid-19 impacts and the associated deferral of medical procedures in the prior year across all of our businesses including Surgery, Interventional Solutions, Vision and Orthopaedics.” Pharmaceutical Medical device sales registered the biggest growth last year, increasing to $27.1bn, up 17.9% compared to 2020. JNJ’s pharmaceutical segment accounted for more than half (55.5%) of total sales in 2021, followed by medical devices at 28.9% and consumer health at 15.6%. Full-year 2021 net earnings jumped by 41.9% YoY to $20.9bn.Īs a result of these higher earnings, Johnson and Johnson has declared a cash dividend of $1.06 per share on the company’s common stock for the first quarter of 2022. The group’s net earnings surged to $4.7bn, nearly triple the $1.7bn seen in Q4 2020. JNJ’s sales in the fourth quarter last year increased to $24.8bn, up 10.4% compared to Q4 2020. Johnson and Johnson reported rising sales and net earnings in 2021 in its financial results released on 25 January 2022. Despite the gain over the past week, the JNJ stock price was 1.8% below where it was at the beginning of the year.Īre you interested in learning more about the outlook for the healthcare group? Read this Johnson and Johnson stock analysis for the latest news and analysts’ JNJ stock forecast before making your investment decision on JNJ shares.
The medical device maker and pharmaceutical group’s shares, traded on New York Stock Exchange (NYSE), rose to $168.38 on 26 January, up 1.1% from $166.58 on 19 January. Higher revenue in 2021 and the positive demand outlook this year boosted healthcare group Johnson and Johnson’s (JNJ) share price over the past week. Johnson and Johnson stock forecast: a positive outlook? – Photo: Shutterstock
0 kommentar(er)
